These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8502824)

  • 21. Tamoxifen: trials, tribulations, and trade-offs.
    Friedman MA; Trimble EL; Abrams JS
    J Natl Cancer Inst; 1994 Apr; 86(7):478-9. PubMed ID: 8133527
    [No Abstract]   [Full Text] [Related]  

  • 22. Tamoxifen for the prevention of breast cancer: no.
    DeGregorio MW; Maenpaa JU; Wiebe VJ
    Important Adv Oncol; 1995; ():175-85. PubMed ID: 7672804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secretory endometrial adenocarcinoma in a tamoxifen user with breast cancer after menopause.
    Wu CJ; Peng YJ; Yu MH; Chen CH
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):88-90. PubMed ID: 17389201
    [No Abstract]   [Full Text] [Related]  

  • 24. Asymptomatic carcinoma of the endometrium in a patient on adjunctive tamoxifen therapy for carcinoma of the breast.
    O'Neill E; Rodríguez Mojica W
    Bol Asoc Med P R; 1992 Feb; 84(2):74-7. PubMed ID: 1388459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.
    Rutqvist LE; Johansson H; Signomklao T; Johansson U; Fornander T; Wilking N
    J Natl Cancer Inst; 1995 May; 87(9):645-51. PubMed ID: 7752269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial cancer and tamoxifen.
    Burke C
    Clin J Oncol Nurs; 2005 Apr; 9(2):247-9. PubMed ID: 15853168
    [No Abstract]   [Full Text] [Related]  

  • 27. Tamoxifen and tumorigenicity: a predictable concern.
    Jordan VC
    J Natl Cancer Inst; 1995 May; 87(9):623-6. PubMed ID: 7752262
    [No Abstract]   [Full Text] [Related]  

  • 28. Side effects of adjuvant treatment of breast cancer.
    Shapiro CL; Recht A
    N Engl J Med; 2001 Jun; 344(26):1997-2008. PubMed ID: 11430330
    [No Abstract]   [Full Text] [Related]  

  • 29. Scientific review of tamoxifen. Overview from a medical oncologist.
    Carlson RW
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-151-S1-7. PubMed ID: 9045312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients.
    Robinson DC; Bloss JD; Schiano MA
    Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endolymphatic stromal myosis associated with tamoxifen use.
    Eddy GL; Mazur MT
    Gynecol Oncol; 1997 Feb; 64(2):262-4. PubMed ID: 9038273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials.
    Jordan VC
    Prog Clin Biol Res; 1988; 262():105-23. PubMed ID: 3287387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR appearance of endometrial carcinoma and mucinous cystadenoma in a postmenopausal patient treated with tamoxifen for breast cancer.
    Joja I; Asakawa T; Ando Y; Shiraiwa M; Shibutani O; Akaki S; Kuroda M; Mizutani Y; Kudo T; Hiraki Y
    Radiat Med; 1998; 16(4):315-9. PubMed ID: 9814431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
    Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
    Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tamoxifen controversy.
    Crabbe WW
    Oncol Nurs Forum; 1996 Jun; 23(5):761-6. PubMed ID: 8792346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas.
    Altaras MM; Aviram R; Cohen I; Cordoba M; Yarkoni S; Beyth Y
    Gynecol Oncol; 1993 May; 49(2):255-8. PubMed ID: 8504996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen and endometrial cancer: from experiment to patient.
    Assikis VJ; Jordan VC
    Recent Results Cancer Res; 1996; 140():61-71. PubMed ID: 8787078
    [No Abstract]   [Full Text] [Related]  

  • 40. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
    Magriples U; Naftolin F; Schwartz PE; Carcangiu ML
    J Clin Oncol; 1993 Mar; 11(3):485-90. PubMed ID: 8383191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.